Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: A joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group

Journal of Clinical Oncology

Volumn 25, Issue 4, 2007, Pages 356-361

  Vassal, Gilles ^a   Couanet, Dominique ^a   Stockdale, Elizabeth ^a   Geoffray, Anne ^a   Geoerger, Birgit ^a   Orbach, Daniel ^a   Pichon, Fabienne ^a   Gentet, Jean Claude ^a   Picton, Susan ^a   Bergeron, Christophe ^a   Cisar, Laura ^a   Assadourian, Sylvie ^a   Morland, Bruce ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; IRINOTECAN; LOPERAMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHILD; CHOLINERGIC SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; LIQUID FECES; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION; DISEASE COURSE; DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; RHABDOMYOSARCOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33846990454     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.1960     Document Type: Article

References (28)

1. Gurney JG, Young JL, Roffers SD, et al: Soft tissue sarcomas, in Ries LAG, Smith MA, Gurney JG, et al (eds): Cancer Incidence and Survival Among Children and Adolescents: United States Surveillance, Epidemiology, and End-Results (SEER) Program 1975-1995. Bethesda, MD, National Cancer Institute, 1999
2. Dagher R, Helman L: Rhabdomyosarcoma: An overview. Oncologist 4:34-44, 1999
3. Breneman JC, Lyden E, Pappo AS, et al: Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21:78-84, 2003
4. Carli M, Colombatti R, Oberlin O, et al: European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: Final results and analysis of prognostic factors. J Clin Oncol 22:4787-4794, 2004
5. Stevens MC, Rey A, Bouvet N, et al: Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology-SIOP Malignant Mesenchymal Tumor. J Clin Oncol 23:2618-2628, 2005
6. Raney BT, CristWM,Maurer HM, et al: Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response: A report for the Intergroup Rhabdomyosarcoma study I. Cancer 52:44-50, 1983
7. Bomgaars L, Berg SL, Blaney SM: The development of Camptothecin analogs in childhood cancers. Oncologist 6:506-516, 2001
8. Hare CB, Elion GB, Houghton PJ, et al: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)- carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 39:187-191, 1997
9. Houghton PT, Cheshire PJ, Hallman JDN, et al: Therapeutic activity of the topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin against human tumor xenografts: Lack of cross resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxy camptothecin. Cancer Res 53:2823-2829, 1993
10. Vassal G, Boland I, Santos A, et al: Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice. Int J Cancer 73:156-163, 1997
11. Vassal G, Terrier-Lacombe M, Bissery MC, et al: Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 74:737-745, 1996
12. Vassal G, Pondarre C, Boland I, et al: Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. Biochimie 80:271-280, 1998
13. Blaney S, Berg SL, Pratt C, et al: A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 7:32-37, 2001
14. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
15. Bomgass L, Kerr J, Berg S, et al: A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatric Blood Cancer 46:50-55, 2006
16. Mugishima H, Matsunaga T, Yagi K, et al: Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol/Oncol 24:94-100, 2002
17. Vassal G, Doz F, Frappaz D, et al: A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852, 2003
18. World Health Organization: Handbook for reporting results of cancer treatment. Geneva, Switzerland, World Health Organization, 1979
19. National Cancer Institute: Investigator's Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by DCTD, NCI. Bethesda, MD, National Cancer Institute, 1993
20. Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
21. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
22. Pappo AS, Lyden E, Breitfeld PP, et al: Irinotecan is active against pediatric rhabdomyosarcoma: A phase II window trial from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Proc Am Soc Clin Oncol 21:393a, 2002 (abstr 1570)
23. Petrilli AS, Jakacki RI, Perek D, et al: Randomized phase II study of carboplatin and irinotecan or irinotecan in 1-21 year old patients with refractory solid tumors. J Clin Oncol 22:14S, 2004 (abstr 8559)
24. Cosetti M, Wexler LH, Calleja E, et al: Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24:101-105, 2002
25. Bisogno G, Riccardi R, Ruggiero A, et al: Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106:703-707, 2006
26. Friedman HS, Petros WP, Friedman AH, et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1515-1525, 1999
27. Crews KR, Stewart CF, Jones-Wallace D, et al: Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8:2202-2209, 2002
28. Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19:1501-1518, 2001